Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,20035038,C(max),"Mean C(max) estimated by a noncompartmental analysis was 17.2 mg/L; t(max,) 2.80 days; terminal t(1/2), 7.63 days; and AUC(0-infinity), 199.3 d.mg/L.",Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20035038/),[mg] / [l],17.2,47885,DB06372,Rilonacept
,20035038,t(max,"Mean C(max) estimated by a noncompartmental analysis was 17.2 mg/L; t(max,) 2.80 days; terminal t(1/2), 7.63 days; and AUC(0-infinity), 199.3 d.mg/L.",Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20035038/),d,2.80,47886,DB06372,Rilonacept
,20035038,terminal t(1/2),"Mean C(max) estimated by a noncompartmental analysis was 17.2 mg/L; t(max,) 2.80 days; terminal t(1/2), 7.63 days; and AUC(0-infinity), 199.3 d.mg/L.",Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20035038/),d,7.63,47887,DB06372,Rilonacept
,20035038,AUC(0-infinity),"Mean C(max) estimated by a noncompartmental analysis was 17.2 mg/L; t(max,) 2.80 days; terminal t(1/2), 7.63 days; and AUC(0-infinity), 199.3 d.mg/L.",Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20035038/),[d·mg] / [l],199.3,47888,DB06372,Rilonacept
